RxDoctor Payments Data

Angela Tedford

Acute Care · Columbus, OHNPI 1700491081

Payments from drug & device makers

$1,882in general payments, 2019–2025

Across 58 payments — averaging $32.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$469
  • Novo Nordisk$344
  • Amgen$214
  • Novartis$199
  • Johnson & Johnson$176
  • Boston Scientific$145
  • plus $335 from 6 others

What the payments were for

  • Food & beverage$1,79295%
  • Education$905%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,882 in reported general payments places this provider in the 85th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$18,868
Medicare patients
177
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$192,154
EntrestoSacubitril/Valsartan79$76,935
Repatha SureclickEvolocumab95$66,556
JardianceEmpagliflozin29$36,496
XareltoRivaroxaban30$25,247
FarxigaDapagliflozin Propanediol13$8,771
Praluent PenAlirocumab12$6,610
Metoprolol Succinate285$3,503
Ranolazine ErRanolazine26$2,736
Atorvastatin Calcium187$1,984
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,859
Ezetimibe112$1,807
Torsemide70$1,407
Rosuvastatin Calcium134$1,152
Amiodarone Hcl26$853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$199$76,93579 claims
Boehringer IngelheimJardiance$108$36,49629 claims
Johnson & JohnsonXarelto$176$25,24730 claims
AstraZenecaFarxiga$469$8,77113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,101 acute care providers in Ohio.

Other acute care in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →